Fig. 1: FAP+ CAFs shield LUAD tumor cells from CD8+ T cell attacks. | Cell Death & Disease

Fig. 1: FAP+ CAFs shield LUAD tumor cells from CD8+ T cell attacks.

From: Targeting LINC01711 in FAP+ cancer-associated fibroblasts overcomes lactate-mediated immunosuppression and enhances anti-PD-1 efficacy in lung adenocarcinoma

Fig. 1

A The infiltration level correlation analysis (Spearman correlation analysis) and cumulative survival analysis (Kaplan-Meier survival analysis) of FAP and CD8 in TIMER database and TCGA-LUAD database (n = 511). B Kaplan–Meier survival analysis between FAP-high (MFI of FAP ≥ 10%, n = 41) and FAP-low (MFI of FAP <10%, n = 15) group in TMA cohort. C Spearman correlation analysis between FAP and CD8 immunofluorescence in TMA cohort (n = 56). D Representative image of FAP and CD8 immunofluorescence in TMA cohort (n = 56). E Flow chart of in vivo and in vitro experiments. F Flow cytometry analysis of in vitro co-culture model (n = 3 biological repeats). The P-value was calculated by two-tailed unpaired t-test. G Representative images, tumor size, and weight of subcutaneous tumors (n = 5 biological repeats, the P-value was determined by two-way ANOVA with Tukey’s multiple comparison test or two-tailed unpaired Student’s t-test). H Flow cytometry analysis of in vivo tumor bearing model (n = 5 biological repeats). The P-value was calculated by two-tailed unpaired t-test. All the results were shown as mean ± S.E.M. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.

Back to article page